Sweden to Receive Scandinavia’s First
TomoTherapy System
Lund University Hospital to Offer Swedish Cancer Patients the Most
Advanced Image-Guided Radiation Therapy Treatments
MADISON, Wis. (Business Wire EON/PRWEB ) July 31, 2008 --
TomoTherapy Incorporated
(NASDAQ: TOMO) announced today that it has extended its reach in Europe
with the first TomoTherapy®
Hi∙Art®
treatment system set to be installed in Scandinavia, at Lund University
Hospital in Sweden.
Jef Van Dam, general manager of TomoTherapy EMEA, said, "TomoTherapy is
extremely pleased to partner with Lund University Hospital. This marks
our entry into the Swedish market with a prestigious institution that
pioneered the use of many technological advances in Scandinavia
and Europe. We look forward to delivering the advanced Hi∙Art
system to continue that tradition."
Lund University Hospital conducted an extensive investigation of all
commercially available intensity-modulated radiation therapy (IMRT)
systems, including arc-based options on conventional platforms, before
making the decision to purchase the TomoTherapy Hi∙Art
system.
Charlott Wictor, strategic purchaser of medical equipment for the Skane
region in Sweden, championed TomoTherapy and helped the purchase become
reality: “This was a great team effort working
with the Lund medical and physics experts to bring this advanced
technology to our Swedish patients. TomoTherapy was clearly the
best choice from both a high technology and economic standpoint.”
Jacob Engellau, M.D., Ph.D., head of radiation oncology at Lund
University Hospital, believes TomoTherapy will have a great
impact on patient treatments. “As a large
center treating 2500 new patients yearly, we are dependent on high
up-time and clinical reliability. The established and clinically
well-implemented TomoTherapy Hi∙Art
was the only system that could meet the demands of our clinic.”
Tommy Knöös,
Ph.D., associate professor and head of radiation physics at Lund
University Hospital, was also an important decision maker in the
process. “We think TomoTherapy is the
most advanced image-guided system for radiotherapy with an integrated
functionality for imaging and localisation of the target volume. It also
produces the most advantageous dose distributions for IMRT,”
according to Knöös.
Added Engellau, “With the Hi∙Art
system, we see obvious clinical advantages for treating complex
radiation target volumes, multiple targets and targets requiring a high
radiation dose with close proximity to healthy organs. Conventional 3D
conformal radiation or IMRT can treat some but not all of these case
types. If the cases can be attempted, we believe the results would be
less conformal, less accurate and with much longer treatment times than
with TomoTherapy.”
While TomoTherapy will be used to treat a wide array of cancers,
the clinical experts at Lund plan to focus on anal, rectal, cervical,
stomach and esophageal cancers. They will also be using the Hi∙Art
system for stereotactic radiosurgery treatments and see greater
possibilities for clinical trials involving simultaneously integrated
boost (SIB) with or without dose escalation.
Lund University Hospital plans to install the TomoTherapy Hi∙Art
system later this year.
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, markets and sells the TomoTherapy®
Hi·Art®
treatment system, an advanced radiation therapy system for the treatment
of a wide variety of cancers. The Hi·Art
treatment system combines integrated CT imaging with conformal radiation
therapy to deliver sophisticated radiation treatments with speed and
precision while reducing radiation exposure to surrounding healthy
tissue. The company’s stock is traded on the
NASDAQ Global Select Market under the symbol TOMO. To learn more about
TomoTherapy, please visit TomoTherapy.com.
Forward-Looking Statements
Statements in this release regarding future events, expectations and
other similar matters, including but not limited to statements using the
terms “look forward to”
or “will”
constitute forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements contained in this press release are subject to risks and
uncertainties that could cause actual results to differ materially from
those anticipated, including but not limited to factors such as our
ability to integrate acquired assets, ability to protect intellectual
property, risks of interruption due to events beyond the company’s
control, and the other risks listed from time to time in TomoTherapy’s
filings with the U.S. Securities and Exchange Commission, which by this
reference are incorporated herein. These forward-looking statements
represent TomoTherapy’s judgments as of the
date of this press release. TomoTherapy assumes no obligation to update
or revise the forward-looking statements in this release because of new
information, future events or otherwise.
©2008 TomoTherapy Incorporated. All rights
reserved. TomoTherapy, the TomoTherapy logo and Hi·Art
are among trademarks, service marks or registered trademarks of
TomoTherapy Incorporated.
Post Comment: Trackback URL: http://www.prweb.com/pingpr.php/RW1wdC1UaGlyLVNpbmctRmFsdS1TaW5nLVNpbmctWmVybw==
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
Share The News
Submit this press release easily to any of these major bookmarking and social media sites.